Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ANEB

ANEB - Anebulo Pharmaceuticals, Inc. Stock Price, Fair Value and News

2.85USD+0.13 (+4.78%)Delayed as of 01 Mar 2024, 02:35 pm ET
Watchlist

Market Summary

USD2.85+0.13
Delayedas of 01 Mar 2024, 02:35 pm
4.78%

ANEB Stock Price

View Fullscreen

ANEB RSI Chart

ANEB Valuation

Market Cap

70.5M

Price/Earnings (Trailing)

-6.72

Price/Sales (Trailing)

833.5

EV/EBITDA

-19.47

Price/Free Cashflow

-7.36

ANEB Price/Sales (Trailing)

ANEB Profitability

EBT Margin

-3910.69%

Return on Equity

-161.73%

Return on Assets

-139.88%

Free Cashflow Yield

-13.58%

ANEB Fundamentals

ANEB Revenue

Revenue (TTM)

92.4K

ANEB Earnings

Earnings (TTM)

-10.5M

Earnings Growth (Yr)

28.99%

Earnings Growth (Qtr)

-9.53%

Breaking Down ANEB Revenue

52 Week Range

2.004.05
(Low)(High)

Last 7 days

14.9%

Last 30 days

18.3%

Last 90 days

31.9%

Trailing 12 Months

-6.9%

How does ANEB drawdown profile look like?

ANEB Financial Health

ANEB Investor Care

Shares Dilution (1Y)

1.17%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202371.1K92.4K00
202207.3K28.6K49.9K
20210000

Tracking the Latest Insider Buys and Sells of Anebulo Pharmaceuticals, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 18, 2023
english aron r.
gifted
-
-
-300,000
-
Dec 18, 2023
english aron r.
gifted
-
-
300,000
-
Nov 13, 2023
english aron r.
acquired
-
-
300,000
-
Dec 17, 2021
english aron r.
bought
2,634
6.5858
400
-
Dec 14, 2021
english aron r.
bought
2,428
5.895
412
-
Dec 03, 2021
english aron r.
bought
26,685
5.93
4,500
-
Dec 02, 2021
english aron r.
bought
73,330
5.3
13,836
-
May 06, 2021
english aron r.
acquired
4,999,750
7.00
714,250
-
May 06, 2021
english aron r.
acquired
5,000,000
7.00
714,286
-

1–9 of 9

Which funds bought or sold ANEB recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 15, 2024
Nantahala Capital Management, LLC
added
100
912,266
2,473,590
0.07%
Feb 14, 2024
VANGUARD GROUP INC
added
584
302,006
370,267
-%
Feb 14, 2024
BANK OF AMERICA CORP /DE/
new
-
10.00
10.00
-%
Feb 14, 2024
Praetorian PR LLC
sold off
-100
-541,627
-
-%
Feb 14, 2024
ADAR1 Capital Management, LLC
new
-
2,945
2,945
-%
Feb 14, 2024
Ikarian Capital, LLC
unchanged
-
-121,554
382,026
0.04%
Feb 14, 2024
22NW, LP
added
5.92
-2,491,090
12,986,400
8.46%
Feb 14, 2024
BOOTHBAY FUND MANAGEMENT, LLC
unchanged
-
-12,051
45,927
-%
Feb 14, 2024
MANGROVE PARTNERS
sold off
-100
-1,219,610
-
-%

1–10 of 19

Are Funds Buying or Selling ANEB?

Are funds buying ANEB calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ANEB
No. of Funds

Recent SEC filings of Anebulo Pharmaceuticals, Inc.

View All Filings
Date Filed Form Type Document
Feb 13, 2024
8-K
Current Report
Feb 13, 2024
10-Q
Quarterly Report
Dec 20, 2023
4
Insider Trading

Peers (Alternatives to Anebulo Pharmaceuticals, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
35.3B
6.8B
-16.59% -47.80%
-7.48
5.15
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.0B
1.8B
-23.99% -31.71%
-43.22
10.41
76.23% 61.08%
16.3B
2.4B
-4.89% -18.90%
97.14
6.73
15.42% 18.43%
13.1B
3.7B
-7.62% -26.87%
21.93
3.55
8.87% 75.42%
MID-CAP
7.5B
396.6M
-2.06% 34.31%
-14.14
18.84
425.83% 18.94%
6.0B
-
-3.85% 226.12%
-9.63
60.35
54.84% -25.61%
4.0B
240.7M
-19.08% -10.99%
-13.4
16.52
-1.03% -92.09%
3.9B
270.6M
8.92% 47.81%
-16.12
14.25
440.80% -27.84%
3.8B
726.4M
-12.60% 32.37%
-62.48
5.27
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
-3.38% -9.50%
26.46
4.74
85.90% -14.05%
687.2M
983.7M
-9.17% -57.89%
-1.26
0.7
-50.36% 17.16%
201.6M
4.9M
-14.18% -58.18%
-1.22
41.23
-57.57% 50.48%
135.5M
881.7K
289.54% 381.25%
-2.86
112.79
-77.61% -13.74%
4.3M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Anebulo Pharmaceuticals, Inc. News

Latest updates
Simply Wall St18 Feb 202412:58 pm

Anebulo Pharmaceuticals, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q2
Operating Expenses-12.9%2,494,3892,864,0413,813,1222,612,0472,325,4841,879,6441,071,1221,554,9242,484,705
  S&GA Expenses-39.3%1,077,2301,774,6991,943,2021,388,2711,207,343964,281858,186839,826678,013
  R&D Expenses30.1%1,417,1591,089,3421,869,9201,223,7761,118,141915,363212,936715,098-
EBITDA Margin23.0%-39.11-50.80-72.46-126-492----
Earnings Before Taxes---------1,554,924-2,472,938
EBT Margin23.0%-39.11-50.80-72.46-126-492----
Net Income10.8%-2,495,580-2,797,971-3,826,952-2,611,835-2,322,742-1,876,491-1,072,991-1,553,395-29,111,739
Net Income Margin21.9%-126-162-213-275-930----
Free Cashflow-30.1%-2,849,246-2,190,545-2,609,420-2,033,922-1,999,256-1,461,263-1,198,753-777,902-3,497,308
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q2
Assets-17.1%8.009.0012.0014.0017.0020.0016.0017.0019.0021.0022.004.004.003.003.00
    Cash Equivalents-22.0%7.009.0011.0014.0016.0019.0015.0017.0018.0019.0020.003.00--3.00
Liabilities41.4%1.001.001.001.001.001.001.000.000.001.000.0011.00---
Shareholder's Equity-22.1%6.008.0011.0013.0016.0019.0015.0017.0019.0020.0021.000.000.000.000.00
  Retained Earnings-4.6%-62.40-59.68-57.20-54.70-51.91-48.08-45.47-43.15-41.27-40.20-38.64-9.53---0.18
  Additional Paid-In Capital1.3%69.0068.0068.0068.0067.0067.0061.0060.0060.0060.0060.000.00---
Shares Outstanding1.2%26.0026.0026.0026.0026.0023.0023.0023.0023.0023.0023.0013.0013.00--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q2
Cashflow From Operations33.5%-1,813-2,726-2,849-2,190-2,609-2,033-1,999-1,461-1,198-777-3,497-828-410-134-150
  Share Based Compensation0%20020023022422620022712594.0034.0011547.0021.0016.00-
Cashflow From Financing----68.16--2486,699----20,176---3,176

ANEB Income Statement

2023-12-31
Condensed Statements of Operations (Unaudited) - USD ($)
3 Months Ended6 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]    
Research and development$ 1,062,672$ 1,869,920$ 2,332,892$ 3,093,696
General and administrative1,697,7871,943,2022,971,2453,331,473
Total operating expenses2,760,4593,813,1225,304,1376,425,169
Loss from operations(2,760,459)(3,813,122)(5,304,137)(6,425,169)
Other (income) expenses:    
Interest expense31,83831,838
Interest income(75,522)(8,816)(130,720)(13,249)
Other59422,646(7,063)26,867
Other (income) expenses, net(43,090)13,830(105,945)13,618
Net loss$ (2,717,369)$ (3,826,952)$ (5,198,192)$ (6,438,787)
Weighted average common shares outstanding, basic25,789,73925,633,21725,711,47824,524,856
Weighted average common shares outstanding, diluted25,789,73925,633,21725,711,47824,524,856
Net loss per share, basic$ (0.11)$ (0.15)$ (0.20)$ (0.26)
Net loss per share, diluted$ (0.11)$ (0.15)$ (0.20)$ (0.26)

ANEB Balance Sheet

2023-12-31
Condensed Balance Sheets - USD ($)
Dec. 31, 2023
Jun. 30, 2023
Current assets:  
Cash and cash equivalents$ 6,644,517$ 11,247,403
Prepaid expenses171,740422,748
Total current assets6,816,25711,670,151
Other assets:  
Loan commitment fees684,516
Total assets7,500,77311,670,151
Current liabilities:  
Accounts payable318,679534,545
Accrued expenses694,877534,256
Total liabilities1,013,5561,068,801
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, $0.001 par value; 2,000,000 shares authorized, no shares issued or outstanding at December 31, 2023 and June 30, 2023
Common stock, $0.001 par value; 50,000,000 and 40,000,000 shares authorized at December 31, 2023 and June 30, 2023, respectively; 25,933,217 and 25,633,217 shares issued and outstanding at December 31, 2023 and June 30, 2023, respectively25,93425,634
Additional paid-in capital68,861,51667,777,757
Accumulated deficit(62,400,233)(57,202,041)
Total stockholders’ equity6,487,21710,601,350
Total liabilities and stockholders’ equity$ 7,500,773$ 11,670,151
ANEB
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. The company was incorporated in 2020 and is based in Lakeway, Texas.
 CEO
 WEBSITEwww.anebulo.com
 EMPLOYEES4

Anebulo Pharmaceuticals, Inc. Frequently Asked Questions


What is the ticker symbol for Anebulo Pharmaceuticals, Inc.? What does ANEB stand for in stocks?

ANEB is the stock ticker symbol of Anebulo Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Anebulo Pharmaceuticals, Inc. (ANEB)?

As of Thu Feb 29 2024, market cap of Anebulo Pharmaceuticals, Inc. is 70.54 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ANEB stock?

You can check ANEB's fair value in chart for subscribers.

What is the fair value of ANEB stock?

You can check ANEB's fair value in chart for subscribers. The fair value of Anebulo Pharmaceuticals, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Anebulo Pharmaceuticals, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ANEB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Anebulo Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether ANEB is over valued or under valued. Whether Anebulo Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Anebulo Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ANEB.

What is Anebulo Pharmaceuticals, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 29 2024, ANEB's PE ratio (Price to Earnings) is -6.72 and Price to Sales (PS) ratio is 833.5. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ANEB PE ratio will change depending on the future growth rate expectations of investors.